National Institutes of Health, a Component of the US Dept. of Health & Human Services

Forschungsverbund Berlin E.v.

Other

Johns Hopkins University

University System of Maryland

The University of Tokyo

New England Biolabs, Inc.

National Institutes of Health

James Inglese

Craig J Thomas

Wei Ping Zheng

Noel Terrence Southall

Wenwei Huang

Matthew Brian Boxer

Jian-kang Jiang

Douglas S Auld

Steven Titus

Bruce M Raaka

Susanne Neumann

Gerd Krause

Patricia Dranchak

Marvin C Gershengorn

Gunnar Kleinau

Amanda P Skoumbourdis

Barbara S Slusher

Joseph P Steiner

Hiroaki Suga

Mark A Hoon

Dana Victor Ferraris

Donald Jeffrey Zack

Tomas Vojkovsky

Clotilde K Carlow

Zhiru Li

Zhiyong Yang

Cynthia Ann Berlinicke

Joseph G Hacia

Hao Yu

Nancy E Braverman

Hans Juergen Solinski

Ryan MacArthur

Danielle L Schmitt

Songon An

Laszlo Hackler

Matthew Boxer

Jian-Kang Jiang

Wei Zheng

A cell-based quantitative high-throughput screening assay to monitor the formation of PFK1-mEGFP clusters by the action of small molecules to identify small molecules that promote intracellular PFK1 clustering in a cell cycle-dependent manner and may be used to treat cancer.

Method of identifying a compound which affects the multienzyme metabolic assembly of glucose metabolism and its association with cell cycle progression in cancer cells

Pharmaceutical compositions comprising a molecular inhibitor of Npr1 are disclosed. Also disclosed are methods of treating, reducing, or preventing acute and/or chronic pruritus in a mammal comprising administering a pharmaceutical composition comprising a molecular inhibitor of Npr1.

Compositions and methods for the inhibition of pruritus

Provided herein are methods of treating Zellweger spectrum disorder (ZSD) in a subject in need thereof or improving peroxisome assembly in a cell in need thereof comprising administering to the subject a therapeutically effective amount of Compounds of Formula I or II.

Compositions and methods for the treatment of Zellweger spectrum disorder

Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.

Peptide inhibitors of phosphoglycerate mutase and methods of use

Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and Rto Rare as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer and anemia, 

Activators of human pyruvate kinase

Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.

Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists

Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.

Compounds and methods of use thereof for treating neurodegenerative disorders

Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and Rto Rare as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer and anemia, Formulas (I); (II). 

Disclosed are pyruvate kinase M2 activators, which are bis sulfonamide piperazinyl and piperidinyl compounds of Formula (I), 2,4-disubstituted 4H-thieno[3,2-c]pyrrole-2-(substituted benzyl)pyridazin-3(2H)-ones of Formula (II) and 6-(3,4-dimethylphenylaminosulfonyl)-3,4-dihydro-1H-quinolin-2-one of formula (III), wherein L, R, R, Rto R, Rand Rare as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer and anemia. 

Activators of the human pyruvate kinase M2 receptor

Growing community of inventors

Bethesda, MD, United States of America

James Inglese